Mason T. Dacus

Mason T. Dacus

Auto-generated profile, based on publicly available information

Mason T. Dacus

John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MSMiguel C. Sobral
Miguel C. Sobral
LCLaura Cabizzosu
Laura Cabizzosu
SKShawn J. Kang
Shawn J. Kang
KRKyle Ruark
Kyle Ruark
ANAlexander J. Najibi
Alexander J. Najibi
DMDavid J. Mooney
David J. Mooney
One driver of the high failure rates of clinical trials for therapeutic cancer vaccines is likely the inability to sufficiently engage conventional dendritic cells (cDCs), the antigen-presenting cell (APC) subset that is specialized in priming antitumor T cells. Here, we demonstrate that, relative to vaccination with an injectable mesoporous silica rod (MPS) vaccine alone (Vax), combining MPS vaccines with CD122-biased IL-2/anti-IL-2 antibody complexes (IL-2cx) drives ~3-fold expansion of cDCs at the vaccination sites, vaccine-draining lymph nodes, and spleens of treated mice. Furthermore, relative to Vax alone, Vax+IL-2cx led to a ~3-fold increase in the numbers of CD8 + T cells and ~15-fold increase in the numbers of NK cells at the vaccination site. Notably, with both the model protein antigen OVA as well as various peptide neoantigens, Vax+IL-2cx induced ~5 to 30-fold greater numbers of circulating antigen-specific CD8 + T cells relative to Vax alone. We further demonstrate that Vax+IL-2cx leads to significantly improved efficacy in the MC38 colon carcinoma model relative to either monotherapy alone, driving complete regressions in 50% of mice in a cDC-dependent manner. Relative to vaccine alone, Vax+IL-2cx led to comparable numbers of CD8 + T cells, but markedly greater numbers of NK cells and activated cDCs in the B16F10 melanoma tumor microenvironment post-therapy. Taken together, these findings suggest that the administration of factors that engage both the cDC-CD8 + T cell and cDC-NK cell axes can boost the potency of therapeutic cancer vaccines.

23 October 2026 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
GNGabriele Nasello
Gabriele Nasello
NLNuria Lafuente-Gómez
Nuria Lafuente-Gómez
LKLeila Krajnovic
Leila Krajnovic
DWDavid T. Wu
David T. Wu
MDMason T. Dacus
Mason T. Dacus
DMDavid J. Mooney
David J. Mooney